Detailed Scientific Program by Days

 

Sunday 24 August 2014

Plenary LectureMarek Vácha

Date: Sunday 24 August 2014
Time: 19:00–19:30
Room: Grand Ballroom

Marek Vácha
Head of Department of Ethics, Charles University, Prague, Czech Republic

Animals: Biomechanisms or Evolving Organisms on the Way to a Reflexive Thought?

Introduction: Dagmar Jirova – WC9 co-chair


Get-Together Party

Date: Sunday 24 August 2014
Time: 19:30-22:00
Room: Grand Ballroom, Summer Terrace and Chez Louis Salon


Monday 25 August 2014

Opening Ceremony

Date: Monday 25 August 2014
Time: 8:30–9:30
Room: Congress Hall II

Dean of the Faculty of Medicine, Charles University – Miroslav Červinka
Member of Czech Parliament, Chair of the Central Commission for Animal Welfare – Radim Fiala
Representative of the Ministry of Agriculture of the Czech Republic – Jiří Hojer
Deputy Director-General for the Food Chain in DG Health and Consumers of European Commission – Ladislav Miko
President of ACT – Herman Koëter
Local Congress Co-Chair – Dagmar Jírová

Black Light Theatre IMAGE – A performance of abstract images you may have never experienced before. The intense darkness of black theatre is full of fantasy. Poetic pictures are approaching you from the mysterious and almost indefinite depth of a black cabinet. You can be sure that your imagination will fully awake.


Plenary LectureMichel Goldman

Date: Monday 25 August 2014
Time: 9:30–10:00
Room: Congress Hall II

Michel Goldman
Executive Director, Innovative Medicines Initiative (IMI), Brussels, Belgium

The rational use of animals in drug development: contribution of the Innovative Medicines Initiative

Introduction: Michael Balls – ACT Board


Break • Poster viewing I

Time: 10:00–10:15


Session II-4b: Risk Assessment – Cosmetics

Co-chairs:
Vera Rogiers, Vrije Universiteit Brussel, Belgium
Carl Westmoreland, Unilever, UK

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Congress Hall II

Presentations:

Introduction

II-4b-061
C. Westmoreland:
Consumer risk assessments for personal care products without the use of data generated in animals.

II-4b-777
H. Kandarova:
Assessment of phototoxic potential of topically applied substances and formulations using 3-D reconstructed human skin models

II-4b-223
V. Rogiers:
Can a retrospective analysis of SCCS toxicological data contribute to the design of a new approach for the safety assessment of cosmetic ingredients with low oral bioavailability?

II-4b-347
R. M. Rodrigues:
Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity testing

II-4b-361
R. J. Dearman:
Toxicogenomics as a WoE tool to investigate false positive responses obtained in the LLNA

II-4b-085
K. Schuetze:
Non-invasive monitoring of drugs and toxic agents based on Raman Laser Spectroscopy

End remarks


Session IX-1: Activity updates from international scientific societies

Co-chairs:
Chantra Eskes, ESTIV, Switzerland
Hajime Kojima, JaCVAM, Japan

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Congress Hall III

Presentations:

IX-1-676
C. Eskes:
ESTIV’s Activities for the Promotion of In Vitro Toxicology

IX-1-769
U. G. Sauer:
Activities of EUSAAT, the European Society for Alternatives to Animal Testing

IX-1-493
E. Hill:
North American society promotes advances in in vitro and in silico toxicology

IX-1-148
A. Turner:
American association for laboratory animal science: past, present and future

IX-1-536
M. L. Chovel:
Cuban Group and the Latin-Ibero-American Network for Alternatives: Initiatives for accelerating the implementation of 3Rs in our continent

IX-1-901
S. Y. Han:
Alternatives to Animal Experiments in Korea: Past Achievements and Present Status of the Korean Society for Alternatives to Animal Experiments (KSAAE)

IX-1-022
H. Kojima:
Activities of JSAAE (Japanese Society for Alternatives to Animal Experiments)


Session VIII-5: Culture of care

Co-chairs:
Jann Hau, University of Copenhagen, Denmark
Susanna Louhimies, DG ENV, EU Commission, Belgium

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Karlín II + III

Presentations:

J. Hau: Introductory lecture: set the scene

VIII-5-486
S. Louhimies:
What constitutes a good culture of care?

VIII-5-663
B. Reed:
Achieving a good ‘culture of care’ – what and how.

VIII-5-169
T. Decelle:
Culture of the 3Rs: Accelerating the Development and the Implementation of Alternatives

Q&A

VIII-5-137
A. Chandna:
The impact of AAALAC accreditation on compliance with animal welfare laws

VIII-5-153
K. Bayne:
Promoting an institutional culture of care and ethics

VIII-5-693
S. Lane:
Implementing an action plan for world class animal care and husbandry at Imperial College London

Q&A

VIII-5-254
J. Bilton:
Toenail trimming in mice – an alternative treatment for ulcerative dermatitis


Session I-5: Bioreactors

Co-chairs:
Toshiyuki Kanamori, AIST, Japan
Katrin Zeilinger, Charité – Medical School, Germany

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Athens + Barcelona

Presentations:

I-5-210
H. Matsui:
Optical cell separation by photodegradable hydrogels for three dimensional cultures

I-5-238
A. Papadimitropoulos:
A three dimensional (3D) perfusion bioreactor-based model of colorectal cancer for chemotherapeutic assessment

I-5-333
K. Ohnuma:
Microfluidic perfusion culture system for culturing human induced pluripotent stem cells under fully defined culture conditions

I-5-407
A. Ahluwalia:
Autonomous bioreactor modules for disease models and detection of systemic toxicity

I-5-419
T. Kanamori:
Cell Function Induction Using Perfusion Culture

I-5-573
K. Zeilinger:
3D multi-compartment bioreactor technology for in vitro pharmacological studies as an alternative to animal testing


Session VII-5: Benefit evaluation

Co-chairs:
Marlies Leenaars, UMCN, The Netherlands
Malcolm Macleod, University of Edinburgh, UK

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Berlin + Brussels

Presentations:

VII-5-087
J. Bailey:
An analysis of the use of dogs in predicting human toxicology and drug safety

VII-5-243
F. R. Stafleu:
Lack of clinical results: are animal experiments still ethically acceptable?

VII-5-337
M. Leenaars:
Added value of research synthesis in laboratory animal science

VII-5-417
M. T. Avey:
Does interpretation of the principle of reduction by ethics committees lead to underpowered studies?

VII-5-653
M. Macleod:
Why considerations of rigour should be central to the ethical review of experiments using animals

VII-5-866
J. Kimmelman:
A Structured Approach for Using Preclinical Studies to Assess Risk/Benefit in Trials and Animal Studies


Session VI-5: Epithelial biobarriers

Co-chairs:
Claus-Michael Lehr, HIPS and Saarland University, Germany
Maria Prieto-Pilar, EURL ECVAM, JRC, Italy

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Vienna + Roma

Presentations:

VI-5-908
C.-M. Lehr:
Modelling mucosal epithelia in state of inflammation

VI-5-932
E. Roblegg:
In-vitro models of the oro-gastro-intestinal mucosa

VI-5-341
S. Constant:
Development of human airway tissue-based assay for respiratory absorption giving input parameters for PBTK modeling

VI-5-864
P. Hayden:
Application of in vitro human airway models for toxicology, drug delivery and disease modeling

VI-5-849
E. Haltner:
Potential of mucosal in vitro models obtaining approval for drug products – Case studies with Caco-2 and Calu-3 cells

VI-5-632
M. Windbergs:
Design and characterization of in vitro models for human skin wounds

VI-5-933
H. Kandarova:
Potential and limitations of reconstructed human skin models in assessing pharmaceutical formulations

Discussion


Session III-2: Funding Agencies and Funding Programs

Co-chairs:
Takashoi Omori, Doshisha University, Japan
Mark Prescott, NC3Rs, UK

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Karlín I

Presentations:

Opening remarks by the Co-Chairs

III-2-793
M. Prescott:
Experience from a UK 3Rs research funder

III-2-024
C. L. Nellemann:
The Danish 3R-Centre

III-2-296
C. Desaintes:
Contribution from the European Research Framework programmes to the 3Rs

III-2-374
G. Schoenfelder:
More than 20 “years” research funding by ZEBET – measures and lmpact

III-2-647
T. Seidle:
Advancing safety science and health research under Horizon 2020 with modern, human biology-based tools

General discussion


Session IX-4: Novel approaches to validation

Co-chairs:
Sonja Beken, FAMHP, Belgium
Maurice Whelan, EURL ECVAM, JRC, Italy

Date: Monday 25 August 2014
Time: 10:15–12:15
Room: Tyrolka

Presentations:

IX-4-634
M. Stephens:
Systematic reviews of test method performance: A case study using the Zebrafish Embryo Test for developmental toxicity

IX-4-713
M. Whelan:
Evolving validation practice to meet the demands of predictive toxicology

IX-4-799
S. Coecke:
The role of European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL) towards internationally accepted harmonised in vitro method standards.

IX-4-854
S. Beken:
Regulatory acceptance of 3R testing approaches for medicinal products

IX-4-925
C. Kelley:
Validation and qualification of new in vitro technologies for drug development

IX-4-939
J. Wang:
Alternative Toxicological Methods for Drug Safety Assessment in China


Poster viewing I

Date: Monday 25 August 2014
Time: 12:15–13:30
Room: Grand Ballroom


Lunch

Time: 12:15–13:30


Session II-10a: Topical Toxicity – Skin

Co-chairs:
Nathalie Alépée, L’Oreal, France
Helena Kandarova, SETOX/MatTek, Slovakia

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Congress Hall II

Presentations:

II-10a-244
N. Alépée:
Use of HPLC/UPLC-photometry for detection of formazan in in vitro Reconstructed human Tissue (RhT)-based test methods to expand their applicability to strongly coloured test substances:

II-10a-377
S. Catoire:
An Immature Human Reconstructed Epidermis Model To Assess Baby Skin Irritancy

II-10a-519
K. Kejlova:
Human experimental data – the ultimate confirmation of in vitro methods relevance for safety and efficacy testing

II-10a-862
M. Corvaro:
Formulation testing in the 21st Century


Session I-4a: 3D Liver models

Co-chairs:
Jens M. Kelm, InSphero AG, Switzerland
Taku Matsushita, Sojo University, Japan

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Congress Hall III

Presentations:

I-4a-015
K. Gellynck:
H3Screen; Promethera’s 3D liver progenitor cell model for hepatotoxicity testing

I-4a-178
S. D. Ramachandran:
In vitro generation of functional organoid structures resembling embryonic liver buds using differentiated, human cells

I-4a-450
T. Matsushita:
Development of hollow fiber type three dimensional (3D) culture module for long term culture of human hepatocytes to evaluate the drug toxicity to liver.

I-4a-612
S. Messner:
Organotypic human HepaRG spheroid cultures for in vitro toxicity studies

I-4a-785
S. Messner:
Characterization of heterotypic 3D human liver microtissues for drug-induced hepatotoxicity testing


Session VIII-2b: Best practice welfare approaches – Mouse

Co-chairs:
Michael Walker, University of Guelph, Canada
Hanno Würbel, University of Bern, Switzerland

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Karlín II + III

Presentations:

VIII-2b-016
P. Jirkof:
Burrowing and nest building behavior as indicators of well-being in laboratory mice

VIII-2b-069
M. Walker:
Improving laboratory mouse welfare and reducing animal numbers through mixed-strain housing

VIII-2b-288
B. N. Gaskill:
The scientific and welfare benefits of the right environmental enrichment for laboratory mice

VIII-2b-475
A. Miller:
The Mouse Grimace Scale (MGS): A clinically useful tool?

VIII-2b-684
F. Sewell:
A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies


Session VI-1a: In vitro disease models – Lung

Co-chairs:
Andreas C. Hocke, Charité, Germany
Horst Spielmann, FU Berlin, Germany

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Palmovka + Rokoska + Hercovka

Presentations:

VI-1a-162
S. Huang:
Efficacy assessment of novel anti-viral, anti-inflammatory and mucolytic agents using Human Airway Epithelium (MucilAir™)

VI-1a-442
O. Danov:
IL-13 induced asthma model in human precision-cut lung slices

VI-1a-466
K. Sewald:
Ex vivo models for asthma, COPD and lung injury in precision cut lung slices (PCLS)

VI-1a-740
P. J. Hayden:
Responses of in vitro asthmatic human airway epithelial cultures to rhinovirus and poly(I:C)

VI-1a-900
A. C. Hocke:
Intravital imaging of human lung tissue for simulation of severe lung infections


Session V-3b: Potency testing of human and veterinary vaccines

Co-chairs:
Lukas Bruckner, Institute of Virology and Immunology, Switzerland
Wlamir Correa de Moura, INCQS/FIOCRUZ, Brazil

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Athens + Barcelona

Presentations:

V-3b-120
W. C. Moura:
Residual live virus detection test for rabies vaccine for human use: a 3Rs proposal for the brazilian pharmacopoeia test method.

V-3b-125
L. Bruckner:
A cell line assay for in-process toxicity and antigenicity testing of clostridium septicum vaccine antigens

V-3b-197
M. Hoonakker:
Functional in vitro testing of the consistency of Bordetella pertussis vaccine production

V-3b-707
S. Uhlrich:
Consistency approaches for the replacement of Diphtheria Tetanus Pertussis potency assays


Session II-13: Endocrine disruption

Co-chairs:
David Dix, EPA, USA
Jean-Lou C. M. Dorne, EFSA, Italy

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Berlin + Brussels

Presentations:

II-13-484
D. Dix:
High Throughput Chemical Screening for Endocrine Disrupting Potential

II-13-542
T. Ramirez:
Inter-laboratory validation of the yeast estrogen and androgen screens for identification of endocrine active substances

II-13-709
J. L. C. M. Dorne:
Integrating toxicokinetics in human and environmental risk assessment of endocrine disrupters

II-13-839
M. Whelan:
Scientific criteria and methods for the identification and assessment of endocrine disrupters in the EU


Session V-1: Pathways based assays in drug development

Co-chairs:
Humberto Pinheiro de Araujo, INCQS/FIOCRUZ, Brazil
M. Belen Tornesi, AbbVie, USA – IQ consortium

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Vienna + Roma

Presentations:

V-1-066
H. Vuorenpää:
Development of Functional Human Cell Based Cardiovascular Construct for Cardiotoxicity Assessment

V-1-229
D. A. Tagle:
Bioengineered organs-on-chips for modeling disease, drug safety and efficacy screening

V-1-295
M. B. Tornesi:
Fishing for Teratogens: A Consortium Effort for a Harmonized Zebrafish Developmental Toxicology Assay

V-1-670
A. Wilmes:
Deciphering mechanisms of cisplatin-induced renal toxicity using a multi-omics-pharmacokinetics approach

V-1-820
R. Sison-Young:
Assessment of current in vitro models at the protein expression level and correlation to the prediction of DILI


Session VIII-4: Avoidance of severe suffering

Co-chairs:
Anna Olsson, IBMC, Portugal
Mark Prescott, NC3Rs, UK

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Karlín I

Presentations:

VIII-4-342
C. Hendriksen:
Humane end-points in animal experimentation

VIII-4-688
F. Sewell:
A global initiative to refine acute inhalation studies through the use of ‘evident toxicity’ as an endpoint: Towards adoption of the Fixed Concentration Procedure

VIII-4-580
K. Lidster:
A refined model of experimental autoimmune encephalomyelitis (EAE) to study neuroprotection in multiple sclerosis (MS)

VIII-4-523
J. V. Roughan:
Inflammation imaging and refinement of post-surgical NSAID dose recommendations in mice


Session IV-5: Intellectual property, data sharing and data ownership

Co-chairs:
Derek J. Knight, ECHA, Finland
Harald Schlatter, Procter & Gamble, Germany

Date: Monday 25 August 2014
Time: 13:30–15:00
Room: Tyrolka

Presentations:

IV-5-317
C. Mahony:
P&G’s approach to data sharing for the Seurat-1 COSMOS project

IV-5-534
M .T. D. Cronin:
Shared toxicity data: adding value to predictive models

IV-5-669
D. J. Knight:
Data sharing and joint submission as tools for avoiding unnecessary testing for registration under the REACH Regulation

IV-5-893
B. Hardy:
Data Sharing of Alternative Evidence in Replacement Research and Safety Assessment supported by OpenTox and ToxBank


Break • Poster viewing I

Time: 15:00–15:15


Session II-8: Meeting new regulatory challenges following the cosmetic ingredients ban – Cosmetics Europe’s research programme on alternatives

Co-chairs:
Patric Amcoff, Cosmetics Europe, Belgium
Horst Wenck, SCT AAT & Beiersdorf, Germany

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Congress Hall II

Presentations:

II-8-084
P. Amcoff:
Meeting new regulatory challenges following the cosmetic ingredients ban – Cosmetics Europe’s research programme on alternatives

II-8-319
C. Mahony:
Systemic Toxicity Alternatives (SEURAT-1 and beyond)

II-8-404
S. Pfuhler:
The Cosmetics Europe animal-free strategy for genotoxicity testing

II-8-575
A. Schepky:
An overview of the cosmetics Europe skin bioavailability and metabolism project

II-8-658
S. Hoffmann:
Cosmetics Europe`s strategy for skin sensitisation safety assessment without animal testing: Data integration

II-8-659
P. McNamee:
Continued developments in the Cosmetics Europe Eye Irritation Task Force strategy and programme for prediction and assessment of ocular irritancy


Session IX-2: Animal welfare implementation across the world

Co-chairs:
Susanna Louhimies, DG ENV, EU Commission, Belgium
Troy Seidle, HSI, Canada

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Congress Hall III

Presentations:

Introduction (S. Louhimies & T. Seidle)

IX-2-488
S. Louhimies:
What has changed for animal welfare in Europe?

IX-2-888
L. Anestidou:
Progress made for animal welfare in the US, Middle East and North Africa

IX-2-728
J. Granjeiro:
CONCEA – Brazilian Council to Control Animal Experimentation

IX-2-846
N. Jukes:
InterNICHE activity in CIS countries and Iran: Review and reflections

IX-2-155
K. Bayne:
Is international harmonization of animal care and use standards progressing as hoped?

IX-2-760
T. Seidle:
A scientific approach to animal replacement policy

Discussion


Session II-6a: Updates on Research Activities from the USA

Co-chairs:
Russell Thomas, EPA, USA
Ray Tice, NIEHS, USA

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Karlín II + III

Presentations:

Introduction to Session (R. Thomas & R. Tice)

II-6a-879
R. Thomas:
The U.S. EPA ToxCast program: Moving from data generation to application

II-6a-930
A. Simeonov:
The National Center for Advancing Translational Sciences (NCATS): Overview of Structure, Processes, and Phase II Screening Results for Tox21

II-6a-614
R. Tice:
The future of Tox21: Improving on coverage, relevance, and outreach

II-6a-848
S. Fitzpatrick:
Adverse outcome pathways can be critical to inform sound regulatory and policy decisions

II-6a-942
P. Carmichael:
ToxCast/Tox21: Modern Approaches for Industry Benefit

Closing comments (R. Thomas & R. Tice)


Session I-4b: 3D Miscellaneous organ models

Co-chairs:
Elaine Faustman, University of Washington, USA
Ellen Fritsche, University of Düsseldorf, Germany

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Palmovka + Rokoska + Hercovka

Presentations:

I-4b-082
A. Stucki:
Mimicking respiration in an advanced in-vitro lung alveolus

I-4b-240
F. Groeber:
Next generation tissue models as a replacement for animal experiments

I-4b-406
E. Faustman:
An organotypic model of testes development: evaluation of diverse compounds and implications for high-content toxicity screening

I-4b-508
T. Heinonen:
Human cell based 3D-functional vasculogenesis/angiogenesis test for identification of angiogenic and embryonic vascular discruptors and to be used as the vascular platform in tissue models

I-4b-744
E. Fritsche:
NPC-derived neurospheres serve as test systems for early neurodevelopmental toxicity: an interspecies comparison of toxicity pathways

I-4b-755
E. Fein:
Organotypic tissue culture as a new in vitro model of human myocardium


Session II-1a: Pathways approaches in toxicology

Co-chairs:
Kim Boekelheide, Brown University, USA
Maurice Whelan, EURL ECVAM, JRC, Italy

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Athens + Barcelona

Presentations:

II-1a-123
W. Buck:
Pathway activation from tissue samples as a predictor of in vivo toxicity profile

II-1a-251
P. Carmichael:
Can cancer safety assessment be conducted solely on the basis of in vitro studies?

II-1a-613
K. Boekelheide:
Cell-based risk assessment relies on a quantitative understanding of toxicity pathways

II-1a-696
K. Paul:
Using adverse outcome pathway analysis to identify gaps in high-throughput screening for thyroid disruption

II-1a-712
M. Whelan:
Advancing integrated approaches to animal-free chemical safety assessment using an Adverse Outcome Pathway framework


Session V-2: Disease models in vivo

Co-chairs:
Nicolas Dudoignon, Sanofi R&D, France
Tobias Schnitzer, Roche Diagnostics, Germany – IQ consortium

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Berlin + Brussels

Presentations:

V-2-077
J. Fernandez:
The Effect of Additional Rodent Enrichment on Local and Systemic Bacterial Infection Models, Hematology, Clinical Chemistry, and Serum Cortisol

V-2-246
A. K. Hansen:
Characterizing the gut microbiota as a way to reduce the group size in rodent studies

V-2-465
E. Sena:
Ischemic preconditioning against myocardial infarction: a systematic review of animal models

V-2-502
P. Clerc:
From scientific failures to policy changes: moving away from animal use in research

V-2-574
P. C. Chandrasekera:
Murine models of human disease: why we must think outside the cage

V-2-606
J. Kimmelman:
Addressing threats to clinical generalizability in preclinical experiments: a feasibility study of sunitinib

V-2-685
H.-W. Tseng:
Combination of YM155, a Survivin Suppressant, with sorafenib: A New Combination Therapy for Human Hepatocellular Carcinoma in Patient-Derived Xenograft models

V-2-746
J. M. Braun:
Refined models for GLP-conform translational studies in the preclinical safety assessment of cell, tissue or organ transplantation with human therapeutic biologicals

V-2-950
R. Claus:
Automated, continuous non-contact infrared monitoring system for assessment and stratification in models of infectious disease


Session III-5: Sharing best practices in LAS education and training

Co-chairs:
Tsutomu Miki Kurosawa, Animal Welfare Research Japan, Japan
Jan van der Valk, Utrecht University, The Netherlands

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Vienna + Roma

Presentations:

Opening remarks by the Co-chairs

III-5-485
D. Anderson:
Training in the Three Rs under Directive 2010/63/EU

III-5-641
G. Griffin:
Animal user training in Canada

III-5-759
T. M. Kurosawa:
Practical training of basic laboratory animal handling technique

III-5-081
J. van der Valk:
The European Platform for LAS Education & Training

III-5-703
G. Griffin:
Harmonization of education and training in laboratory animal science (presented by Javier Guillen)

General discussion concerning:
• elements to be included in LAS training
• different standards for those carrying out experiments and those taking care of the animals
• responsibility for international harmonization of standards


Session IV-2: Scientific reporting standards (in vivo and in vitro)

Co-chairs:
Mardas Daneshian, University of Konstanz, Germany
Merel Ritskes-Hoitinga, Radboud University, The Netherlands

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Karlín I

Presentations:

IV-2-540
N. H. Franco:
Classifying editorial policies on animal use in science: the EXEMPLAR scale

IV-2-586
M. Ritskes-Hoitinga:
Animal studies: more than a modern sacrifice ritual?

IV-2-677
N. J. Osborne:
Research reporting standards, scientific validity, animal welfare and the 3Rs

IV-2-750
K. Lidster:
The ARRIVE guidelines: Improving the reporting of in vivo research

IV-2-904
M. Daneshian:
Quality standards for publications dealing with in vitro test systems


Session VII-1: Ethical and normative aspects of human-based approaches

Co-chairs:
Brett Cochrane, Dr Hadwen Trust, UK
Jurgen Hescheler, Cologne, Germany

Date: Monday 25 August 2014
Time: 15:15–17:15
Room: Tyrolka

Presentations:

VII-1-100
J. Johnson:
Creating safe spaces for ethical reflection by animal researchers

VII-1-312
E. Cihalova:
The use of animals in research or alternative methods – pros and cons

VII-1-474
D. Bunton:
Use of fresh functional human tissue as a highly predictive alternative to animal research

VII-1-629
J. Hescheler:
Practical and ethical issues with using stem cells in research


Plenary LectureRoman Mokrý

Date: Monday 25 August 2014
Time: 17:15–17:45
Room: Congress Hall II

Roman Mokrý
Policy Officer, DG Health and Consumers of European Commission, Brussels, Belgium

European strategy for 3Rs and replacement of animal experiments (example of cosmetics sector)

Introduction: Dagmar Jirova – WC9 co-chair


Russell and Burch 3Rs Award Ceremony

Date: Monday 25 August 2014
Time: 17:45-18:00
Room: Congress Hall II


Poster viewing I

Date: Monday 25 August 2014
Time: 18:00–19:00
Room: Grand Ballroom


Welcome Reception

Date: Monday 25 August 2014
Time: 19:30-23:00
Place: Public Spa (Občanská plovárna)


Tuesday 26 August 2014

Plenary LectureUwe Marx

Date: Tuesday 26 August 2014
Time: 9:00–9:30
Room: Congress Hall II

Uwe Marx
Founder & Chief Scientific Officer, TissUse GmbH, Berlin, Germany

Human-on-a-Chip – a paradigm shift from animal testing

Introduction: Horst Spielmann – ACT Board


Award Ceremony

Date: Tuesday 26 August 2014
Time: 9:30–9:45
Room: Congress Hall II


Break • Poster viewing II

Time: 9:45–10:00


Session II-12a: Skin sensitization

Co-chairs:
Gavin Maxwell, Unilever, UK
Tzutzuy Ramirez, BASF, Germany

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Congress Hall II

Presentations:

II-12a-079
J. Barroso:
Progress in the implementation of the EURL ECVAM strategy on skin sensitisation

II-12a-115
A. Mehling:
The beauty (and accuracy) of simplicity: The 2 of 3’s of testing for skin sensitization hazard identification and beyond

II-12a-117
A. Natsch:
Predicting skin sensitizing potency based on in vitro data from KeratinoSens™ and kinetic peptide binding: Opportunities and limitations

II-12a-350
J. Jaworska:
Bayesian Integrated Testing Strategy for Skin Sensitization Potency – ITS-3 the next generation

II-12a-181
G. Maxwell:
From Pathways to People: Applying the Skin Sensitisation AOP to Risk Assessment


Session I-3a: Tissue on a chip / Human-on-a-chip

Co-chairs:
Suzanne Fitzpatrick, Johns Hopkins University, USA
Uwe Marx, TU Berlin, Germany

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Congress Hall III

Presentations:

I-3a-694
D. Sakharov:
A dynamic human-on-chip platform for neurotoxicity studies

I-3a-316
J. van den Eijnden:
Human beating heart on a chip for cardiotoxicity testing as an example case of the Dutch organ-on-chip initiative

I-3a-913
J. M. Kelm:
Developments towards physiologic in vitro models in Switzerland

I-3a-584
S. Fitzpatrick:
In vitro microphysiological systems: Advancing regulatory science through innovation

I-3a-791
A. Van Der Meer:
Human organs on chips as replacements for animal testing


Session IX-5: Regulatory acceptance of alternatives

Co-chairs:
Anne Gourmelon, OECD, France
Derek J. Knight, ECHA, Finland

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Karlín II + III

Presentations:

IX-5-107
M.-J. Schiffelers:
Regulatory acceptance and use of the Extended One Generation Reproductive Toxicity Study within Europe

IX-5-425
S. Cheng:
Promote the use and outspread of alternative methods in China through standardization and administration acceptance

IX-5-652
K. Taylor:
Can the ADAPT principles help regulatory authorities implement the 3Rs?

IX-5-671
D. J. Knight:
Possible roles for non-standard methods in the REACH Registration

IX-5-797
A. Gourmelon:
Regulatory acceptance of methods intended to become OECD Test Guidelines

II-10-264
N. Su:
The Multi-Center Study (MCS) of an alternative method by Chinese CAIQ/CIQ laboratories: the validation of in vitro skin irritation testing method based on EpiSkin model

Discussion


Session III-1: 3Rs in academic education, training programs and anticipated needs

Co-chairs:
Gilly Griffin, CCAC, Canada
Monika Schäfer-Korting, FU Berlin, Germany

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Palmovka + Rokoska + Hercovka

Presentations:

Opening remarks by the Co-Chairs

III-1-624
M. Schäfer-Korting:
The Berlin-Brandenburg research platform BB3R and integrated graduate school

III-1-642
G. Griffin:
Training for the Three Rs – the CCAC research fellowships in animal policy training

III-1-190
B. I. Choe:
Assessing Current Practice on the Three Rs Literature Search: Analysis and Key Findings from the National Survey

III-1-315
M. A. Akbarsha:
Doerenkamp-Zbinden Foundation’s vision to reduce animal use in education and research in India through MGDC adequately realized

III-1-396
D. Fry:
Integrated 3Rs education

III-1-454
G. Alves:
An integrated practical course on cell biology on in vitro cytotoxicity assays for Brazilian health/biology undergraduate students

III-1-554
E. Lilley:
Use of animals for the purposes of education and training

Closing remarks by the Co-Chairs


Session II-15: Genotoxicity/Carcinogenicity

Co-chairs:
Rolf Fautz, KAO Europe, Germany
David Kirkland, Kirkland Consulting, UK

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Athens + Barcelona

Presentations:

II-15-050
D. Kirkland:
Mammalian cell results with Ames-positive chemicals – correlations with presence or absence of in vivo genotoxic or carcinogenic activity

II-15-405
S. Pfuhler:
Impact of OECD guideline revisions and availability of reconstructed human skin-based methods on animal use in genotoxicity testing

II-15-237
A. Poth:
Cell transformation tests: Current status of the SHE and Bhas 42 test system

II-15-063
G. Hendriks:
ToxTracker: a cell-based reporter assay that provides mechanistic insight into the genotoxic properties of chemicals

II-15-224
G. Ates:
Alternative solutions for misleading positive mutagenicity/genotoxicity results of cosmetic substances?


Session II-3: Computational modelling and chem-informatics

Co-chairs:
Makoto Hayashi, BSRC, Japan
Ann Richard, EPA, USA

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Berlin + Brussels

Presentations:

II-3-673
M. Honma:
Use of QSAR Tools for Hazard Identification of Genotoxic Impurities in Pharmaceuticals

II-3-356
Y. Sakuratani:
Utilization status and future development of HESS repealed dose toxicity prediction system

II-3-787
C. Yang:
Read-across at the Crossroad of Chemoinformatics and Regulatory Science

II-3-857
S. Boyer:
Being more certain about uncertainty in computational toxicology modeling

II-3-546
R. Huang:
Quantitative high throughput profiling of the Tox21 10K compound library for environmental hazards

II-3-721
A. Richard:
A knowledge-informed chemotype approach to mining the ToxCast/Tox21 chemical-data landscape


Session II-6b: Updates on Activities from Japan

Co-chairs:
Yoshihiro Ohmiya, AIST, Japan
Noriho Tanaka, HATANO, Japan

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Vienna + Roma

Presentations:

II-6b-026
H. Kojima:
Japanese Project “ARCH-Tox” for the Future Chemicals Management Policy: Research and Development of in vitro and in vivo Assays for Internationally Leading Hazard Assessment and Test Methods

II-6b-114
F. Saito:
Tox-Omics Project: Development of methods to detect multi-toxic effects using gene expression analysis

II-6b-565
M. Oshimura:
Towards the development of invitro assay for hazard assessment using human/mouse artificial chromosomes

II-6b-592
K. Saito:
Development of novel in-vitro neurotoxicity screening tests using mouse ES cells-derived neurons

II-6b-655
Y. Nakajima:
Generation of reporter cell lines by combined use of multicolor luciferases and artificial chromosome vector


Session I-1: Virtual tissue models

Co-chairs:
Jan G. Hengstler, IFADo, Germany
Thomas B. Knudsen, EPA, USA

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Karlín I

Presentations:

I-1-729
K. H. Watanabe:
A model of early ovarian development as a future tool in toxicity testing

I-1-743
E. Fritsche:
Novel computational approaches for high content image analyses (HCA) of organoid 3D neurosphere cultures in vitro.

I-1-816
J. Wambaugh:
High-throughput PBPK and Microdosimetry: Cell-level Exposures in a Virtual Tissue Context

I-1-837
T. B. Knudsen:
Multiscale modeling and simulation of embryogenesis for in silico predictive toxicology

I-1-887
S. G. Clendenon:
Building Multiscale Simulations to Analyze Mechanisms of Developmental Toxicity

I-1-889
J. G. Hengstler:
Virtual liver approaches

I-1-890
T. Waldmann:
Use of transcriptomics approaches in human cell-based DNT testing


Session VIII-1b: Non-human primate use and welfare

Co-chairs:
Jaco Bakker, BPRC, The Netherlands
Melanie Graham, University of Minnesota, USA

Date: Tuesday 26 August 2014
Time: 10:00–12:00
Room: Tyrolka

Presentations:

VIII-1b-092
J. Bakker:
Refinement of non-human primate disease models and procedures at the BPRC

VIII-1b-126
M. Graham:
A holistic approach to refinement improves medical management and safety in nonhuman primate disease models

VIII-1b-143
M. Dennis:
The use of advanced imaging to refine vaccine and therapeutic studies with non human primates

VIII-1b-150
R. D. Sarazan:
Simultaneous PK/PD: Automated blood sampling and CV telemetry in conscious nonhuman primates

VIII-1b-467
J. Veth:
Refinement of non-human primate studies by development of adjuvants with less adverse effects

VIII-1b-471
J. Bajramovic:
Workshop report: 'Alternative methods for the use of non-human primates in biomedical research'


L’Oréal Round Table on 3Rs

Sharing Ethical Beauty: education, promotion, information on 3Rs
Round table conference with international experts

Date: Tuesday 26 August 2014
Time: 12:15–13:15
Room: Congress Hall II

Invited speakers:

  • Mohammad A. Akbarsha,  Bharathidasan University, India
  • Shujun Cheng, AQSIQ, China
  • José Cotovio, L’Oréal Research & Innovation, France
  • Hervé Groux, Immunosearch, France
  • Robert Kavlock, US EPA
  • Daiki Kyotani, Nikoderm, Japan

For more details click here.


Poster viewing II

Date: Tuesday 26 August 2014
Time: 12:00–13:30
Room: Grand Ballroom


Lunch

Time: 12:00–13:30


Session II-10b: Topical Toxicity – Eye

Co-chairs:
João Barroso, EURL-ECVAM, Italy
Pauline McNamee, Procter & Gamble, UK

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Congress Hall II

Presentations:

II-10b-142
E. Adriaens:
Retrospective analysis of the Draize test for serious eye damage/eye irritation: importance of understanding the in vivo endpoints under UN GHS / EU CLP for the development and evaluation of in vitro test methods

II-10b-046
J. Barroso:
EURL ECVAM – Cosmetics Europe prospective validation study of Reconstructed human Tissue-based test methods for serious eye damage/eye irritation testing

II-10b-615
H. Sakaguchi:
The predictive capacity and inter-laboratory reproducibility of the Short Time Exposure (STE) test for assessing eye irritation

II-10b-158
M. Watanabe:
Pre-validation study of Vitrigel-EIT (Eye Irritancy Test) method

II-10b-207
H. Groux:
Development of EYEIRR-IS®, an toxicogenomic assay using the Skinethic HCE model for evaluating chemical ocular irritation potency.


Session VIII-2a: Best practice welfare approaches – Mouse

Co-chairs:
Robert Hubrecht, Universities Fed. Animal Welfare, UK
Joanne Zurlo, CAAT, USA

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Congress Hall III

Presentations:

VIII-2a-028
G. Fleetwood:
Contribution of animal care and welfare to 3Rs in the pharmaceutical industry

VIII-2a-284
J. G. Fernandes:
Refinement and experimental design in publications: a longitudinal case study of ALS research

VIII-2a-666
R. Hubrecht:
Welfare in the research environment: Is what we have as good as it gets?

VIII-2a-675
J. Zurlo:
Social housing as the norm for social species of laboratory animals

VIII-2a-804
M. J. Castelhano-Carlos:
PhenoWorld: increased welfare in a new paradigm for housing and evaluation of rodent behaviour.


Session V-3a: Potency testing of human and veterinary vaccines

Co-chairs:
Jean-Michel Chapsal, Sanofi-Pasteur, France
Coenraad Hendriksen, Utrecht University, The Netherlands

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Karlín II + III

Presentations:

V-3a-108
M.-J. Schiffelers:
Replacing the NIH test for rabies vaccine potency testing: a synopsis of drivers and barriers

V-3a-147
L. Bruckner:
The deletion of the target animal batch safety test from monographs in the European Pharmacopoeia and waiving possibilities at VICH level

V-3a-340
C. Hendriksen:
The consistency approach in lot release testing of vaccines

V-3a-462
J. M. Chapsal:
Toward the replacement of the Rabies NIH potency test: International Working Group for Alternatives to NIH test


Session II-1b: Pathways approaches in toxicology

Co-chairs:
Katie Paul, Bayer CropScience, USA
Mathieu Vinken, Vrije Universiteit Brussel, Belgium

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Palmovka + Rokoska + Hercovka

Presentations:

II-1b-010
M. Vinken:
Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury

II-1b-376
N. Kleinstreuer:
Constructing, quantifying, and validating an adverse outcome pathway for vascular development toxicity

II-1b-468
C. Willett:
Building on shared experience to advance practical application of pathway-based toxicology: repeat-dose liver toxicity

II-1b-499
J. Ezendam:
Promises and challenges in constructing an adverse outcome pathway for chemical sensitization of the respiratory tract

II-1b-843
D. Dix:
An Adverse Outcome Pathway (AOP) Framework for Screening for Potential Endocrine Disruption


Session II-14: Reproductive & developmental toxicology

Co-chairs:
George Daston, Procter& Gamble, USA
Koichi Saito, Sumitomo Chemical Co., Japan

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Athens + Barcelona

Presentations:

II-14-248
L. E. Knudsen:
Animal-free Toxicology: The Use of Human Tissue to Replace the Use of Animals — Examples from Human Biomonitoring and Human Placental Transport Studies

II-14-588
K. Saito:
Approaches to detecting embryotoxicity using embryonic stem cells with luminescence analysis

II-14-598
G. Daston:
An exposure-based validation list for developmental toxicity assays

II-14-656
L. Y. Tang:
Evaluations of in vitro embryotoxicity tests for Chinese herbal medicines


Session II-16a: Inhalation toxicology – Nano

Co-chairs:
Marianne Geiser, University of Bern, Switzerland
Robert Landsiedel, BASF, Germany

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Berlin + Brussels

Presentations:

II-16a-054
J. B. Sorli:
Acute lung toxicity of nanofilm spray product-in vitro versus in vivo correlation.

II-16a-094
M. Geiser:
Nano aerosol chamber for realistic in-vitro toxicity studies – NACIVT

II-16a-429
S. Chortarea:
Next-level in vitro testing strategy to study the effects of carbon nanotube aerosols.

II-16a-439
U. G. Sauer:
Pulmonary toxicity of nanomaterials: a critical review of in vitro and in vivo studies


Session VI-1b: In vitro disease models – Infection

Co-chairs:
Mario Fabri, University of Cologne, Germany
Claus-Michael Lehr, HIPS and Saarland University, Germany

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Vienna + Roma

Presentations:

VI-1b-393
C. de Souza Carvalho:
In vitro triple culture of inflamed human intestine as a model to investigate nanoparticle safety and efficacy

VI-1b-525
F. Laudisi:
Regulation of pro- and anti-inflammatory human Th17 cell properties

VI-1b-581
M. Fabri:
Vitamin D-dependent antimicrobial pathways in human macrophages

VI-1b-639
M. Müller:
A human in vitro allergy model showing allergen specific immune responses using house dust mite or grass pollen allergen


Session VI-3: Human biomarkers – honouring André Schrattenholz

Co-chair:
Barry Hardy, Douglas Connect, Switzerland

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Karlín I

Presentations:

VI-3-919
K. Groebe:
Human biomarkers of disease, from discovery to validation and test development

T. Hartung: Biomarkers – the convergence of predictive endpoints for in vitro, in vivo, clinical and epidemiological studies?

VI-3-918
B. Hardy:
Use of Alternative Evidence in Replacement Research and Safety Assessment supported by OpenTox and ToxBank

VI-3-920
G. J. Myatt:
The development, use and interpretation of in silico models to support the ICH M7 guideline

VI-3-807
M. Moreno-Villanueva:
The Automated FADU assay: An Alternative Method for Monitoring DNA Repair in Human Studies

II-2-863
P. Jennings:
In vitro to in vivo translational biomarkers

Biography of Prof. André Schrattenholz available here.


Session IV-1: Information requirements on project proposals

Co-chairs:
David Anderson, European Commission & Pentlands Management Systems, UK
Kirsty Reid, Eurogroup for Animals, Belgium

Date: Tuesday 26 August 2014
Time: 13:30–15:00
Room: Tyrolka

Presentations:

Introduction

IV-1-483
S. Louhimies:
Information requirements for project proposals under EU Directive 2010/63/EU

IV-1-322
J. Joya:
Animal ethics approval and monitoring process in an Australian institution

IV-1-789
L. F. Mikkelsen:
Requirements on project proposals in Singapore

IV-1-494
Y.-W. Kim:
Public trust in animal research practices


Break • Poster viewing II

Time: 15:00–15:15


Session II-5: Discussion session: Application in decision making and testing strategies

Co-chairs:
Silke Gabbert, Wageningen University, The Netherlands
Joanna Jaworska, P&G, Belgium

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Congress Hall II

Presentations:

II-5-133
N. Kleinstreuer:
Using in vitro HTS methods to identify endocrine disruptors

II-5-349
J. Jaworska:
Evidence analysis in a Bayesian ITS

II-5-353
J. Gosling:
A Bayesian approach to expert judgment of uncertainty in skin sensitisation risk assessment

II-5-440
R. Landsiedel:
Nanomaterial grouping and concern-driven integrated approaches to nanomaterial testing and assessment

II-5-538
M. Miyazawa:
Data integration of non-animal tests for the development of a test battery to predict skin sensitizing potential and potency of chemicals

II-5-603
S. Gabbert:
The economics of optimising sequential testing strategies: The case of assessing skin sensitisation hazard of cosmetic ingredients

II-5-909
T. Hartung:
Toward Systems Toxicology – Modeling complexity from reductionist information sources


Session II-7: Update from Europe – Alternative testing strategies program

Co-chairs:
Catherine Mahony, Procter & Gamble, UK
Horst Spielmann, FU Berlin, Germany

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Congress Hall III

Presentations:

II-7-167
T. Steger-Hartmann:
Can data sharing in the pharmaceutical industry contribute to 3R? – Exploring the value of the IMI eTOX database

II-7-504
A.-N. Richarz:
Computational approaches for the safety assessment of cosmetics-related chemicals: results from the COSMOS Project

II-7-589
J. Kleinjans:
carcinoGENOMICS – main outcomes

II-7-630
J. Hescheler:
ESNATS

II-7-835
C. Mahony:
Safety Evaluation Ultimately Replacing Animal Testing – evolution of the SEURAT strategy

II-7-902
B. van der Burg:
The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals

II-7-701
S. Scholz:
Identification of opportunities and limiting steps for reduction, replacement and/or refinement of animal experiments used in environmental risk assessment in European regulation


Session III-3: Innovative teaching and training tools

Co-chairs:
Nick Jukes, InterNICHE, UK
Stephan J. Sigrist, FU Berlin, Germany

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Karlín II + III

Presentations:

Opening remarks by the Co-Chairs

III-3-497
S. J. Sigrist:
The Potential of Drosophila in Neurosciences – Education of Undergraduates and Junior Researchers

III-3-882
N. Jukes:
A review of alternative tools and approaches in education and training

III-3-247
K. Hansen:
Evaluation of the Multimediaroom / Training Clinic at the Norwegian University of Life Sciences

III-3-516
A. Knight:
The birth of ‘SimDonkey’: the develop of a high fidelity donkey patient simulator

III-3-600
H. A. Braun:
The Real and Virtual Laboratory: Computer Simulations in Life Science Education and Research

General discussion and closing remarks


Session VII-3a: Ethical evaluation

Co-chairs:
Anna Olsson, University of Porto, Portugal
Katy Taylor, BUAV, UK

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Palmovka + Rokoska + Hercovka

Presentations:

VII-3a-649
K. Taylor:
Harm: benefit analysis – if no projects fail the test has the system itself failed?

VII-3a-104
A. Brønstad:
Update from the AALAS-FELASA WG on harm-benefit analysis

VII-3a-558
I. A. S. Olsson:
Harm-benefit analysis of animal experimentation: Lack of conceptual clarity and underlying moral disagreement

VII-3a-783
H. Golledge:
Is the concept of euthanasia (a good death) for laboratory animals a myth?

VII-3a-884
K. Millar:
Ethical analysis and an Endpoint Matrix: Opening up the harm and benefit calculus


Session VIII-3: Humane principles in experimental techniques and benefits of 3Rs

Co-chairs:
Jan-Bas Prins, FELASA, Leiden University, Medical Center, The Netherlands
Tim Sangster, Charles River Laboratories, UK

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Athens + Barcelona

Presentations:

VIII-3-062
M. Rose:
Applying the concept of wellbeing to the advancement of Refinement

VIII-3-415
B. A. Lidbury:
Fluorescent Target Array reduces mouse numbers while assessing multiple post-vaccination T-cell responses

VIII-3-583
T. Sangster:
Microsampling a Bioanalytical View

VIII-3-618
P. V. Turner:
Validation of pain-related grimace scales in preweaned laboratory animals

VIII-3-775
E. Törnqvist:
Decreased levels of discomfort in trained mice at experimental procedures, assessed by facial expression

VIII-3-853
N. Hasiwa:
European refinement initiative – science-based refinement


Session II-11: Repeated dose toxicity

Co-chairs:
Gladys Ouédraogo, L’Oreal, France
Michael Schwarz, University of Tübingen, Germany

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Berlin + Brussels

Presentations:

II-11-232
L. Truong:
A quantitative model of systemic toxicity using ToxCast and ToxRefDB

II-11-318
G. Daston:
Cheminformatic Approaches for Analog-based Toxicity Assessments

II-11-344
G. Ouedraogo:
Repeated dose systemic toxicity: which predictive methods?

II-11-610
K. Sewald:
Alternative model for repeated dose inhalation toxicity using precision-cut lung slices

II-11-648
B. Blaauboer:
Repeated-dose toxicity prediction based on in vitro toxicity data: possibilities and limitations

II-11-651
K. Taylor:
The added value of the 90-day repeated dose toxicity test for low toxicity chemicals

II-11-922
C. Verfaillie:
Generation of a liver-simulating device mimicking the complex structure and function of the human liver suitable of long-term toxicity testing from drugs and cosmetics


Session I-7: Monitoring (telemetry)

Co-chairs:
Michael Hoffmann, Bayer AG, Germany
R. Dustan Sarazan, Data Sci. Int., USA

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Vienna + Roma

Presentations:

Introduction

I-7-209
R. D. Sarazan:
Animal instrumentation and telemetry: Past, present & future

Telemetry in Small Animal Models

I-7-121
C. N. Boyle:
Continuous blood glucose levels and food intake after RYGB surgery in rats

I-7-899
P. F. Fabene:
EEG telemetry as a gold standard for rodent studies in neurodegeneration

Telemetry in Large Animal Models

I-7-089
M. Hoffmann:
Telemetric Monitoring in Preclinical Development

I-7-176
A. El Amrani:
Simultaneous Use of Implanted and Jacketed External Telemetry – A Contribution Towards the 3R’s


Session II-17: Ecotoxicology

Co-chairs:
Michelle R. Embry, HESI, USA
Stefan Scholz, UFZ, Germany

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Karlín I

Presentations:

II-17-643
C. A. LaLone:
Perspectives on pathway perturbation: focused research to enhance 3R objectives

II-17-665
M. Minghetti:
Rainbow trout gut cell line (RTgutGC) as a model for fish intestinal epithelia

II-17-700
S. Scholz:
The fish embryo test beyond validation – improvements of the fish embryo acute toxicity test and potential applications for reduction of chronic fish toxicity tests

II-17-704
M. R. Embry:
It is time to develop the ecological Threshold of Toxicological Concern (Eco-TTC)

II-17-765
M. Leonard:
Alternatives to animal testing for the environmental assessment of cosmetic and personal care products / a review of achievements, challenges, vulnerabilities and future needs

II-17-827
D. Knapen:
Development of an alternative testing strategy for the fish early life-stage test for predicting chronic toxicity.


Session IV-4: Information systems and databases

Co-chairs:
Annett Janusch-Roi, EURL ECVAM, JRC, Italy
Ursula G. Sauer, EUSAAT, Germany

Date: Tuesday 26 August 2014
Time: 15:15–17:15
Room: Tyrolka

Presentations:

IV-4-189
B. I. Choe:
Development of the New Korean Guidance on the Three Rs Search: Adaptations and Use of the European Commission's Search Guide

IV-4-297
M. Wood:
Considering alternatives: searching for the 3Rs

IV-4-524
A. Swiatek:
Promotion of the use and development of alternatives by the European Commission: The EURL ECVAM databases

IV-4-689
D. M. Kopustinskiene:
Sources of information needed to comply with requirements of Directive 2010/63//EU on animal welfare in the field of biomedical sciences in Lithuania – a researcher’s point of view

IV-4-831
K. Adams:
Single database versus multi-database searches for alternatives: a comparative review

Overall discussion


Plenary LectureNancy Gillett

Date: Tuesday 26 August 2014
Time: 17:15–17:45
Room: Congress Hall II

Nancy Gillett
Corporate Executive Vice President & Chief Scientific Officer,
Charles River Laboratories, Wilmington, MA, USA

Industrial Perspectives on the 3Rs and Animal Welfare

Introduction: Andrew Rowan – ACT Board


Charles River Laboratories’ Excellence in Refinement Award

Date: Tuesday 26 August 2014
Time: 17:45-18:00
Room: Congress Hall II


Poster viewing II

Date: Tuesday 26 August 2014
Time: 18:00–19:00
Room: Grand Ballroom


Enjoy Prague

Date: Tuesday 26 August 2014
Time: 19:30-22:00
Place:


Wednesday 27 August 2014

Plenary LectureRoman Kolar

Date: Wednesday 27 August 2014
Time: 9:00–9:30
Room: Congress Hall II

Roman Kolar
Deputy Director, Animal Welfare Academy, Neubiberg, Germany

How long must they suffer? Success and failure of our efforts
to end the animal tragedy in laboratories

Introduction: Gilly Griffin – ACT Board


Award Ceremony

Contribution to the development of toxicology in vitro methods

Date: Wednesday 27 August 2014
Time: 9:30–9:45
Room: Congress Hall II


Break • Poster viewing III

Time: 9:45–10:00


Session II-12b: Skin sensitization

Co-chairs:
João Barroso, EURL-ECVAM, Italy
Andreas Natsch, Givaudan Schweiz AG, Duebendorf, Switzerland

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Congress Hall II

Presentations:

II-12b-346
K. S. Zeller:
In-house validation and technology transfer of the GARD assay for the prediction of sensitizing compounds

II-12b-399
H. Groux:
Assessment of SENS-IS®, a 3D reconstituted epidermis based model for quantifying chemical sensitization potency : results of an inter-laboratories study.

II-12b-817
K. Reisinger:
Cosmetics Europe`s strategy for skin sensitisation safety assessment without animal testing: The toolbox

II-12b-160
M. Hirota:
Development of an artificial neural network model for risk assessment of skin sensitization using human Cell Line Activation Test (h-CLAT), Direct Peptide Reactivity Assay (DPRA) and KeratinoSens™

II-12b-533
S. Martinozzi Teissier:
Integrating cosmetic industrial needs in skin sensitization Integrated Approaches to Testing and Assessement (IATA).


Session IX-3: Activity updates from international validation centres

Co-chairs:
Warren Casey, NICEATM/ICCVAM, USA
Valérie Zuang, EURL ECVAM, JRC, Italy

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Congress Hall III

Presentations:

IX-3-017
H. Kojima:
JaCVAM update

IX-3-388
V. Zuang:
EURL ECVAM’s approach to the global acceptance of alternative methods

IX-3-293
P. Prieto:
EURL ECVAM strategy to avoid and reduce animal use in acute systemic toxicity

IX-3-560
W. Casey:
A New Vision and Direction for ICCVAM and NICEATM

IX-3-570
C. Röhl:
Alternative methods to animal experiments – ongoing activities in Germany

IX-3-619
S. J. Sohn:
Activities of Korean Center for the Validation of Alternative Methods (KoCVAM) to promote alternative test method in Korea

IX-3-867
O. Presgrave:
The Brazilian Centre for Validation of Alternative Methods (BraCVAM) and the establishment of the validation process in Brazil


Session VI-1c: In vitro disease models – Skin

Co-chairs:
Monika Schäfer-Korting, FU Berlin, Germany
Ellen van den Bogaard, Radboud University, The Netherlands

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Karlín II + III

Presentations:

VI-1c-522
E. van den Bogaard:
In vitro inflammatory 3D skin models of psoriasis and eczema as pre-clinical screening tools

VI-1c-625
M. Schäfer-Korting:
Approaching an in-vitro model for atopic dermatitis

VI-1c-282
L. Wallmeyer:
PPAR agonists do not exhibit their beneficial effects in inflammatory skin diseases by upregulating FLG expression

VI-1c-782
M. Klausner:
An In vitro reconstructed psoriasis tissue model for evaluation of drug therapeutics

VI-1c-124
E. Warrick:
Modeling hypersensitivity of human skin towards UV radiation from the DNA-repair deficient genetic syndrome xeroderma pigmentosum


Session VII-4: Distress evaluation

Co-chairs:
Elliot Lilley, RSPCA, UK
Harikrishnan Vijayakumar Sreelatha, SCTIMST, Kerala, India

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Palmovka + Rokoska + Hercovka

Presentations:

VII-4-059
A. Smith:
Norecopa: using a national consensus-platform to promote the 3Rs

VII-4-140
V. S. Harikrishnan:
Distress Evaluation in Experiments using Rodents

VII-4-308
D. Anderson:
Severity assessment under directive 2010/63/eu – a continuous process

VII-4-556
E. Lilley:
Assessing welfare – why and how

VII-4-635
N. H. Franco:
The case for refinement: making prospective and retrospective assessment of the severity of procedures count for animal welfare in biomedical research


Session VI-4a: Absorption, distribution, metabolism and excretion (ADME)

Co-chairs:
Olavi Pelkonen, University of Oulu, Finland
Amin Rostami-Hodjegan, University of Manchester, UK

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Athens + Barcelona

Presentations:

VI-4a-539
O. Pelkonen:
Living cell as a tool in in vitro toxicity testing platforms

VI-4a-798
S. Coecke:
Gaining insight into xenobiotic biotransformation: the CYP induction in vitro method

VI-4a-914
H. Clewell:
In Vitro to In Vivo Extrapolation and Reverse Dosimetry

VI-4a-916
A. Rostami-Hodjegan:
The Added Value of Physiologically-Based Pharmacokinetic in Modelling the Target Tissue Exposure for PKPD Analysis

VI-4a-424
M. L. H. Vlaming:
SPECT-CT imaging to study the pharmacokinetics of radiolabelled antisense oligonucleotides (AONs) in vivo


Session II-2: Systems biology

Co-chairs:
Ralf Herwig, MPI Molecular Genetics, Germany
Richard Judson, U.S. EPA, USA

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Berlin + Brussels

Presentations:

II-2-362
R. Stierum:
In vitro data combined with human disease data to improve toxicological hazard assessment: the ASAT Knowledge Base

II-2-395
A. J. White:
Development of a mechanistic based model for Nrf2 and oxidative stress in the context of the Adverse Outcome Pathway framework.

II-2-602
R. Judson:
Using Alternative Approaches to Prioritize Testing for the Universe of Chemicals with Potential for Human Exposure

II-2-674
J. Kanno:
Percellome toxicogenomics project as the 3R-toxicology and the foundation of in vitro- and in silico-toxicology

II-2-828
C. Wierling:
Pathway analysis and mathematical modeling of cellular systems for personalized medicine


Session III-6: Discussion: The role of journals in implementing the 3Rs

Moderator:
Iratxe Puebla, PLoS One, UK

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Vienna + Roma

Panelists:

Susan Trigwell, ATLA, FRAME, UK

Sonja von Aulock, ALTEX, CAAT, Switzerland

Thomas B. Knudsen, Elsevier B.V., The Netherlands

Presentations:

Opening remarks by the Moderator

III-6-953
I. Puebla:
PloS ONE consideration of ethical aspects in publication of animal-based research

III-6-941
S. Trigwell:
Journal Publishers: Who exactly do we serve?

III-6-952
S. von Aulock:
ALTEX – documenting and disseminating visions and progress on alternatives to animal experiments

III-6-954
T. B. Knudsen:
Supporting RRRs through “Special Issues” and the role of journals in “big data”

Moderated discussion on the role of journals in implementing the 3Rs to include:

  • What steps can be taken to raise awareness about the 3Rs among authors, particularly in settings/countries where standards may not be consistent with internationally acceptable guidelines
  • Can journals/publishers do more to increase consistency and standards regarding the handling and care of animals in research
  • How can journals encourage and facilitate a higher quality of reporting of animal research and better study designs, can we draw any lessons from standards applied to clinical research?
  • Open Access vs subscription based publications: does the publication model have a bearing on standards for animal research and how this is reported?
  • Impact factor and how this relates to publications involving animal experiments

Session I-2: High throughput screening (HTS) models

Co-chairs:
Marco Prunotto, Roche, Switzerland
Ray Tice, NTP/NIEHS, USA

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Karlín I

Presentations:

M. Prunotto & R. Tice: Introduction to Session

I-2-049
Y. Kimura:
Evaluation of the Multi-ImmunoTox assay (MITA) composed of 3 human cytokine reporter cell lines by examining the immunological effects of drugs

I-2-511
J. M. Kelm:
The throughput-compatible embryonic stem cell test (EST)

I-2-622
V. Tonkopii:
The Usage of Daphnia magna for Screening of Muscarinic Cholinoreceptors Antagonists

I-2-225
S. Verstraelen:
Evaluation of zebrafish embryo as alternative model to predict hepatotoxicity

I-2-257
W. Boyd:
Developmental effects of ToxCast™ chemicals on alternative animal models: C. elegans and zebrafish

I-2-644
R. Tice:
The Tox21 “1500 genes” high throughput transcriptomics project


Session IX-7: Harmonising ways to capture pathway-knowledge in toxicology

Co-chairs:
Hristo Aladjov, OECD, France
Clemens Wittwehr, EURL ECVAM, JRC, Italy

Date: Wednesday 27 August 2014
Time: 10:00–12:00
Room: Tyrolka

Presentations:

IX-7-286
C. Wittwehr:
Adverse Outcome Knowledge Base (AOP-KB)

IX-7-426
H. Aladjov:
Organizing the adverse outcome pathways knowledge – the Effectopedia way

IX-7-699
K. Sullivan:
Using the AOP Knowledgebase to record an Adverse Outcome Pathway for respiratory sensitisation

IX-7-771
J. Wignall:
Using DRAGON to organize data and decisions for AOPs

IX-7-829
R. Benigni:
Skin sensitization AOP proof of concept implementation in the OECD QSAR Toolbox


Bjorn Ekwall Memorial Award Session

Co-chairs:
Ada Kolman, BEMF, Sweden
Hanna Tähti, FICAM, Finland

Date: Wednesday 27 August 2014
Time: 12:00–13:30
Room: Congress Hall II

X-3-572
T. Heinonen:
BEMF award lecture 2014: Better science with human cell-based organ and tissue models

X-3-640
M. Stephens:
A history of the 3Rs in toxicity testing: From Russell and Burch to 21st century toxicology


Poster viewing III

Date: Wednesday 27 August 2014
Time: 12:00–13:30
Room: Grand Ballroom


Lunch

Time: 12:00–13:30


Session II-4a: Risk Assessment – Nano

Co-chairs:
Harvey Clewell, The Hamner Institutes for Health Sciences, USA
Keith Houck, US EPA, USA

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Congress Hall II

Presentations:

II-4a-928
K. Houck:
In Vitro Testing of Engineered Nanomaterials in the EPA’s ToxCast Program

II-4a-157
S. Schindler:
Search for and implementation of integrated testing strategies in nanotoxicology

II-4a-430
T. Heinonen:
Comparison of cytotoxicity of engineered nanoparticles in mouse BALB/c 3T3 fibroblasts, rat NR8383 macrophages and human U937 monocytes

II-4a-447
T. Titma:
Cytotoxicity of eleven metal oxide nanoparticles

II-4a-455
O. Danov:
Biological impact of modified inhalable carbon black nanoparticles assessed in cell and tissue culture models

II-4a-492
T. Baccarin:
Cytotoxicity of nanoemulsions formulated with Punica granatum seed oil and ethyl acetate fraction from peel extract


Session VII-3b: Ethical evaluation

Co-chairs:
David Anderson, European Commission & Pentlands Management Systems, UK
Herwig Grimm, University of Veterinary Medicine, Vienna, Austria

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Congress Hall III

Presentations:

VII-3b-226
J. Guillen:
Ethical evaluation process: international approaches, issues and assessment

VII-3b-274
H. Binder:
Dignity of the animal: weighing of interests in the context of the Swiss animal welfare act

VII-3b-306
D. Anderson:
Project evaluation under directive 2010/63/eu

VII-3b-752
H. Grimm:
Ethics within legal limits? Considering ethical aspects in harm-benefit analyses against the background of legal frameworks

VII-3b-845
N. Alzmann:
The Austrian catalogue of criteria to objectify the harm-benefit analysis within the evaluation of projects using living animals


Session II-10c: Topical Toxicity – Phototox

Co-chairs:
Abigail Jacobs, USFDA, USA
Manfred Liebsch, Foundation SET, Germany

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Karlín II + III

Presentations:

II-10c-378
U. Pfannenbecker:
In vitro phototoxicity testing: 16 years of experience with a test strategy using the 3T3 Neutral Red Uptake Phototoxicity Test (3T3 NRU PT) and the EpiDerm Phototoxicity Test

II-10c-715
L. R. Gaspar:
Antioxidant potential and phototoxicity of new UV-filters candidates based on marine natural compounds

II-10c-719
H. Kojima:
The ROS in vitro phototoxicity assay for ICH

II-10c-260
S. Aizawa:
Development of an in vitro tiered approach to evaluate phototoxic potential

II-10c-935
A. Jacobs:
Update on ICHS10-photosafety testing without animals


Session I-4c: Novel technology for 3D cell cultures

Co-chairs:
Pankaj Karande, Rensselaer Polytechnic Institute, USA
Toshiaki Takezawa, NIAH, Japan

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Palmovka + Rokoska + Hercovka

Presentations:

I-4c-168
T. Takezawa:
Collagen vitrigel membrane chamber useful for fabricating 3d-culture models composed of epithelial, mesenchymal and/or endothelial cells and its advantages for ADME/Tox studies

I-4c-236
A. Rossi:
Functionalized electrospun nanofibers for the development of a 3D skin model

I-4c-473
S. Nakamura:
Solubilized matrix from decellularized liver as a functional ECM to reproduce in vivo micro-environment in in vitro culture

I-4c-544
P. Karande:
Design and fabrication of human skin by three-dimensional bioprinting

I-4c-667
L. Kanninen:
Nanofibrillar cellulose hydrogel enables flexible 3D cell culturing


Session VIII-1a: Non-human primate use and welfare

Co-chairs:
Paul Honess, Bioculture Group, UK
Patricia V. Turner, University of Guelph, Canada

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Athens + Barcelona

Presentations:

VIII-1a-428
M. Prescott:
Refining the use of non-human primates in research: the NC3Rs as a catalyst for change

VIII-1a-098
K. Descovich:
Can facial expression identify pain responses in rhesus macaques (Macaca mulatta)?

VIII-1a-761
P. V. Turner:
Development of resources for refining research primate use: APV primate retirement guidelines

VIII-1a-551
P. Honess:
Training primates through the supply chain from breeder to laboratory

VIII-1a-897
A. Rowan:
Nonhuman Primate Use in North America: Overview, Trends and Important Considerations for the Future


Session II-9: Exposure

Co-chairs:
Robert Landsiedel, BASF, Germany
John Wambaugh, EPA, USA

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Berlin + Brussels

Presentations:

II-9-345
J. Jaworska:
Computational PBTK workflow to assess toxicity from in vivo dermal exposure

II-9-811
K. McNally:
A probabilistic model of human variability in physiology with application to QIVIVE

II-9-813
J. Wambaugh:
Forecasting Exposure in Order to Use High Throughput Hazard Data in a Risk-based Context

II-9-815
C. Goebel:
Extrapolation of systemic availability assessing skin absorption and epidermal and hepatic metabolism of aromatic amine hair dyes in vitro


Session II-1c: Pathways approaches in toxicology

Co-chairs:
Ralf Herwig, MPI Molecular Genetics, Germany
Lena Smirnova, CAAT, USA

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Vienna + Roma

Presentations:

II-1c-838
H. Hogberg:
Pathways of toxicity as a predictive tool for safety assessment

II-1c-391
T. Ramirez:
Metabolomics in vitro: a new approach for systemic toxicity – first applications for chemical grouping

II-1c-521
R. Herwig:
Pathway level interpretation of toxicogenomics data

II-1c-212
M. Al Sharif:
PPARγ-related hepatotoxic mode-of-action: quantitative characterization and in silico study of the molecular initiating event involving receptor activation


Session VII-2: Ethics of using animals

Co-chairs:
Roman Kolar, Animal Welfare Academy, Germany
Kate Millar, University of Nottingham, UK

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Karlín I

Presentations:

VII-2-053
B. Reed:
Openness, transparency and public engagement on the use of animals in research and testing – recent developments.

VII-2-122
C. Linzey:
Why animal suffering matters

VII-2-151
S. Wolfensohn:
A system for retrospective assessment of cumulative severity to identify targeted refinements

VII-2-185
D. Weary:
Openness and accountability of animal research: results of an expert forum

VII-2-621
K. Reid:
Analysis of the ethical review process of projects to be funded under the European Union’s Horizon 2020 Framework Programme


Session I-6: High-content imaging

Co-chairs:
William R. Mundy, EPA, USA
Bob van de Water, Leiden University, The Netherlands

Date: Wednesday 27 August 2014
Time: 13:30–15:00
Room: Tyrolka

Presentations:

I-6-597
W. R. Mundy:
Use of High Content Imaging (HCI) to screen for developmental neurotoxicity

I-6-892
B. van de Water:
Towards a High Throughput Microscopy Pathway in Toxicity Reporter Platform for Chemical Safety Assessment

I-6-875
I. Shah:
Using high-content imaging to analyze cell-state trajectories and biological tipping points for chemical exposures

I-6-886
M. Beilmann:
High-Content Imaging as a Tool for Nonclinical Drug Safety Investigations

I-6-757
V. Huck:
Intravital multiphoton tomography for non-invasive in vivo analysis of human skin


Break • Poster viewing III

Time: 15:00–15:15


Session IX-8: Towards harmonisation in the application of alternative approaches within chemical regulation and management

Co-chairs:
Bruno Hubesch, Cefic, Belgium
Nicole Kleinstreuer, NICEATM, USA

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Congress Hall II

Presentations:

IX-8-633
N. Ball:
Addressing residual uncertainties to enhance read-across: an Industry perspective

IX-8-749
J. de Knecht:
OECD revised guidance on grouping of chemicals

IX-8-896
K. de Raat:
Assessment of read-across: An ECHA perspective

IX-8-924
S. Cheng:
Application and Uptake of alternative methods in China: Where does read-across fit?


Session IX-6: Breaking down barriers and promoting international cooperation on 3Rs

Co-chairs:
Rodger Curren, IIVS, USA
Nick Jukes, InterNICHE, UK

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Congress Hall III

Presentations:

IX-6-006
G. Cozigou:
EPAA – a key player in shaping the future of 3Rs

IX-6-039
J. Coenen:
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) in 3Rs Leadership Group: The Pharmaceutical Industry’s Promotion of Alternatives

IX-6-496
K. Sullivan:
A seat at the table: Advocating for replacement at the OECD

IX-6-503
R. Curren:
Lack of infrastructure can be a barrier to the acceptance of 3Rs methods; education and training can provide the solution

IX-6-585
S. Fitzpatrick:
A process for regulatory science development and application

IX-6-608
T. Ramirez:
Implementing the 3R methods and hurdles for their application – a perspective from the chemical industry

IX-6-883
N. Jukes:
International collaboration: Case study of InterNICHE in India


Session V-4: Medical devices and Biologicals

Co-chairs:
Tobias Schnitzer, Roche Diagnostics, Germany – IQ consortium
Gianni Dal Negro, GlaxoSmithKline, UK – IQ consortium

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Karlín II + III

Presentations:

V-4-200
C. Spohr:
Establishment of a 3 R method for batch potency testing of bovine tuberculin

V-4-363
E. Balks:
Proteomic analysis of tuberculin purified protein derivatives

V-4-593
G. B. Stevens:
Towards a full-function molecular-based assay for Botulinum Neurotoxin

V-4-705
R. McFarland:
Incorporation of the 3R’s into preclinical testing programs to support cellular and gene therapy product clinical trials that are regulated by US FDA

V-4-885
K. Cussler:
The history of the mouse safety test for sera and vaccines


Session VI-2: Use of stem cells in screening

Co-chairs:
Mario Beilmann, Boehringer-Ingelheim, Germany
Adrian Roth, Hoffmann-La Roche, Switzerland

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Palmovka + Rokoska + Hercovka

Presentations:

VI-2-545
E. Faustman:
Defining normal developmental dynamics for human in vitro neuronal differentiation – applications for setting a baseline for adverse outcome assessments

VI-2-907
W. R. Mundy:
Neural Stem Cells as Screening Tools for Developmental Neurotoxicity

VI-2-275
A. E. M. Seiler:
The DNT-EST: A predictive embryonic stem cell test for developmental neurotoxicity testing in vitro

VI-2-905
K. Kolaja:
Stem cell derived tissues and the 3Rs: application in drug discovery and development

VI-2-532
H. R. Lu:
Human Stem Cell-Derived Cardiomyocytes In Cardiac Safety Research

VI-2-906
R. Passier:
Development of cardiovascular disease models in humans using iPS cells


Session VI-4b: Absorption, distribution, metabolism and excretion (ADME)

Co-chairs:
Romeo Cecchelli, University of Artois, France
Heleen Wortelboer, TNO, The Netherlands

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Athens + Barcelona

Presentations:

VI-4b-313
A. Rossi:
Organ-like three dimensional test systems

VI-4b-672
V. Gouliarmou:
Development of standards for characterising and describing in-vitro human hepatic metabolic clearance methods

VI-4b-711
H. M. Wortelboer:
New approach to predict human oral absorption using porcine intestinal tissue, abundance data and biorelevant matrices

VI-4b-836
M.-P. Dehouck:
Prediction of the brain distribution of drugs in human using in vitro human blood-brain barrier model derived from stem cells.

VI-4b-891
M. Sacha:
In-Vitro Buccal delivery and release of Caffeine from Guarana extract


Session II-16b: Inhalation toxicology – Non-nano

Co-chairs:
Michaela Aufderheide, Cultex, Germany
Samuel Constant, Epithelix, Switzerland

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Berlin + Brussels

Presentations:

II-16b-218
M. Hittinger:
Coculture of autologous human macrophages and epithelial cells for investigation of airborne particle safety

II-16b-464
K. Sewald:
Pre-validation of the ex vivo model precision-cut lung slices (PCLS) for prediction of acute inhalation toxicity

II-16b-557
M. Liebsch:
Validation requirements for alternative methods in inhalation toxicology – case study of a German two phase prevalidation project

II-16b-617
S. Constant:
Cellular based systems for investigating the toxicity effects of inhalable substances

II-16b-762
M. Aufderheide:
In vitro exposure strategies for addressing acute and „chronic” effects of airborne compounds


Session VIII-6: Transgenic animals – Approaches to reduction and refinement in the production and use of GM mice

Co-chairs:
Coenraad Hendriksen, Utrecht University, The Netherlands
Boris Jerchow, MDC Molecular Medicine, Germany

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Vienna + Roma

Presentations:

VIII-6-182
J. Parker-Thornburg:
Refinements for implant surgery: The effects of different anesthetic agents on pregnancy and pup survival.

VIII-6-310
M. Raspa:
INFRAFRONTIER-EMMA’s contribution to 3Rs and the significant reduction in the number of experimental animals

VIII-6-370
D. Fink:
Quantitation of fluorescence intensity in mice – a novel genotyping approach of fluorescently labeled transgenic mouse models

VIII-6-620
J.-B. Prins:
Surplus animals in breeding: is there room for reduction?

VIII-6-943
B. Jerchow:
Generation of Genetically Modified Mouse Models: The Role of the International Society for Transgenic Technologies in Refinement and Reduction

VIII-6-944
X. Rairdan:
Nuclease Technology Reduces Animals Use and Improves Timeline for Making Mouse Models

VIII-6-947
S.-W. Lin:
Reducing and verifying off-target effects when generating genetically modified animal models using genome editing technologies


Session III-4: Implementing the “Montreal Declaration on the Synthesis of Evidence” (panel discussion)

Co-chairs:
Gilly Griffin, CCAC, Canada
Merel Ritskes-Hoitinga, Radboud University, The Netherlands

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Karlín I

III-4-073
J. van Luijk:
Systematic reviews of animal studies; missing link in translational research?

III-4-541
M. Ritskes-Hoitinga:
Implementation of the Montreal Declaration on the Synthesis of Evidence

G. Griffin: Introduction – background to the Montreal Declaration

Questions to be addressed by panelists:

J. van Luijk: What is synthesis of evidence, what is a systematic review

M. Avey: Why do we think that systematic reviews will help to implement the Three Rs

S. Hoffmann: Systematic reviews and evidence based toxicology

M. Macleod: Are systematic reviews of animal based studies being conducted? What are they telling us?

N. Osborne: Why are reporting guidelines important

L. Anestidou: Using systematic reviews to address reproducibility issues

M. Ritskes-Hoitinga: Next Steps –international symposia, work with the Cochrane Collaboration, results of Tabula Rasa

General sum up and discussion


Session IV-3: Retrospective analysis / non-technical summaries (2010/63)

Co-chairs:
Barbara Grune, ZEBET BfR, Germany
Stephen Ryder, Home Office, UK

Date: Wednesday 27 August 2014
Time: 15:15–17:15
Room: Tyrolka

Presentations:

IV-3-283
B. Grune:
Establishing a web-based IT system for publishing Non-technical project summaries in Germany

IV-3-292
D. Anderson:
Requirements for non-technical summaries and retrospective assessment under Directive 2010/63/EU

IV-3-382
S. Ryder:
Annual statistical reports and actual severity

IV-3-453
T. Bengtsen:
Experience with publication of non technical summaries

IV-3-766
C. Bornestaf:
Making numbers count: 3R gains from animal statistics

Round Table Discussion

Moderator:
Ursula G. Sauer, EUSAAT, Germany
Round Table Participants:
Presenters from Session IV-3 joined by Kirsty Reid and Kenneth Applebee


Plenary LectureHe Zhengming

Date: Wednesday 27 August 2014
Time: 17:15–17:45
Room: Congress Hall II

He Zhengming
Director, National Institutes for Food and Drug Control (NIFDC), Beijing, China

Future perspectives for alternatives to animal testing in China

Introduction: Herman Koëter – ACT Board


ALTEX Award Ceremony

Date: Wednesday 27 August 2014
Time: 17:45-18:00
Room: Congress Hall II


Poster viewing III

Date: Wednesday 27 August 2014
Time: 18:00–19:00
Room: Grand Ballroom


Gala Dinner “In Art Nouveau”

Date: Wednesday 27 August 2014
Time: 19:30-23:00
Place: Municipal House


Thursday 28 August 2014

Plenary LectureRobert J. Kavlock

Date: Thursday 28 August 2014
Time: 9:00–9:30
Room: Congress Hall II

Robert J. Kavlock
Deputy Assistant Administrator for Science, Office of Research and Development, US EPA, Washington DC, USA

Lessons Learned from ToxCast and Prospects for the Future

Introduction: Thomas Hartung – ACT Board


JSAAE Poster Award Ceremony

Date: Thursday 28 August 2014
Time: 9:30–9:45
Room: Congress Hall II


Break

Time: 9:45–10:00


Session X-1: Young Scientists Travel Award Short Presentations

Co-chairs:
Lucia Li, FU Berlin, Germany; The Chinese University of Hong Kong, Hong Kong
Manfred Liebsch, Foundation SET, Germany

Date: Thursday 28 August 2014
Time: 10:00–12:00
Room: Congress Hall II

Presentations:

X-1-152
T. Hasenberg:
Emulating the human vasculature in a multi-organ-chip platform

X-1-186
S. S. Htwe:
A 3D Culture System For Investigating Inflammatory Responses In Human Lung

X-1-250
C. Catarino:
In vitro skin corrosion as a pre-validation study of Reconstructed Human Epidermis in house developed

X-1-276
L. Grohmann:
Biotransformation of testosterone and 2,4-toluenediamine by human skin and reconstructed tissues

X-1-434
S. M. Burm:
In vitro models for neuroimmunological diseases

X-1-445
O. Huttala:
Human in vitro adipogenesis assay for testing modulators of adipogenesis

X-1-472
A. Lang:
Simulating the first phase of bone fracture healing in vitro – Possible or not?

X-1-834
G. Harris:
A human iPSC-derived 3D model for the assessment of gene/environment interactions during neurodevelopment

X-1-926
C. Bignon:
Use of reconstructed human epidermis as alternative models for efficiency studies against the penetration of organophosphates


Session X-2: Cosmetics around the world

Co-chairs:
Troy Seidle, HSI, Canada
Yu Zhang, Humane Society International, China

Date: Thursday 28 August 2014
Time: 10:00–12:00
Room: Congress Hall III

Presentations:

Introduction (T. Seidle & Y. Zhang)

X-2-756
C. Mansfield:
Introduction to the evolution in global cosmetics regulation

X-2-690
A. K. Pradhan:
Commitment of Government of India to make available only cruelty free cosmetics

X-2-698
S. Amundson:
Advancing legislation and policy in the United States to end animal use in cosmetics safety testing

X-2-720
H. Stuart:
Cosmetics animal testing in Australia: are normative standards adequate?

X-2-732
J. Granjeiro:
Ban of animal use in cosmetic products safety assessment: Brazilian Scenario

X-2-770
Y. Zhang:
On cosmetics animal testing and be Cruelty free campaign in China

X-2-772
B. Seo:
South Korea's evolving cosmetics regulations and investment in animal testing alternatives

X-2-679
E. McIvor:
Ending cosmetics animal testing in the EU and beyond

Discussion


Session IX-9: Workshop – Establishing criteria for an independent 3R-index: “Access to 3R's”

Co-chairs:
Herman Koëter, Orange House Partnership, Belgium

Date: Thursday 28 August 2014
Time: 10:00–12:00
Room: Karlín II+III

Presentations:

Introduction to the workshop

P. Kustermans: The power of benchmarking; lessons learned from the Access to Medicine Index

G. Fleetwood: The value of measuring and ranking 3R implementation in Industry – experience from the Access to Medicines Index

IX-9-531
C. Krul:
TNO and SliM project – Designing Access to 3Rs

IX-9-531
C. Krul:
3Rs in Corporate Social Responsibility programs – possibilities for an independent 3R-Index

Round Table Discussion


Session I-3b: Regulatory science panel discussion
Human-on-a-chip – Advancing regulatory science through innovation and worldwide networking for alternative testing

Moderator:
Horst Spielmann, FU Berlin, Germany

Date: Thursday 28 August 2014
Time: 10:00–12:00
Room: Palmovka + Rokoska + Hercovka

Panelists:

Suzanne Fitzpatrick, Johns Hopkins University, USA

Wang Jufeng, National Center for Safety Evaluation of Drugs, China

Hajime Kojima, JaCVAM, Japan

Sonja Beken, FAMHP, Belgium

Russian regulatory authorities

Andries Van Der Meer, Harvard University, USA

Uwe Marx, TU Berlin, Germany

Presentation:

I-3b-921
S. Fitzpatrick
and U. Marx: Human-on-a-chip – Advancing regulatory science through innovation and worldwide networking for alternative testing


Closing Ceremony

Date: Thursday 28 August 2014
Time: 12:00–13:00
Room: Congress Hall II

The “ACT President’s Session”
speaker: ACT President Herman Koëter
The “WC10 Invitation Session”
presenters: WC10 Co-Chairs Robert J. Kavlock and Joanne Zurlo
The “Official WC9 Closing Ceremony”
WC9 Co-Chairs Dagmar Jírová and Horst Spielmann and ACT President Herman Koëter

 

 

Last update: 26 August 2014